Table 2.

Disproportionality signal analysis by reporting odds ratio (ROR) and the information component (IC) for pembrolizumab vs. database for 2017–2023. Slash (/): no ROR was calculated since no QT prolongation was reported in the database.

	ROR (95% CI)	IC (97.5% CI)
Cardiac failure	1.69 (1.44–1.97)	0.75 (0.48–1.37)
Atrial fibrillation	1.43 (1.18–1.72)	0.51 (0.19–1.26)
Myocardial infarction	1.22 (1.00–1.49)	0.28 (−0.06–1.09)
Pericardial disease	6.41 (5.54–7.41)	2.64 (2.39–3.22)
Myocarditis	33.87 (29.98–38.26)	4.91 (4.71–5.39)
QT prolongation	/	/